miscarriage

Noninvasive prenatal testing can uncover pregnancies at risk of miscarriage, New Scientist reports.

The firm reported $3.5 million in revenue for the three months ended Dec. 31, 2016, and $12.9 million for the full year.

The firm reported 29 percent growth in its overall testing revenues, driven mainly by higher reproductive test volume and higher per-test revenue.

CombiMatrix said the move will increase access to the test in the state for women experiencing recurrent pregnancy loss.

The company's testing was successful in more than 90 percent of cases over almost four years, and detected a wide variety of abnormalities.

The company reported an 18 percent increase in the number of reproductive health tests completed during the quarter. 

The company feels it could be an attractive target for mergers, but is also keeping an eye out for IP acquisition options of its own.

The company said its revenue increase was driven by gains in test volume, particularly in miscarriage analysis and preimplantation genetic screening for couples undergoing IVF.

The research project, led by Kathy Niakan of the Francis Crick Institute, will involve editing several genes thought to be important to embryo development.

The UK Human Fertilisation & Embryology Authority is to consider an application submitted by researchers seeking to perform gene editing on human embryos.

Pages

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.